The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictive value of circulating tumor cells positive for VEGFR expression in patients with advanced colorectal cancer undergoing treatment with FOLFOX plus bevacizumab.
M. Jose Serrano
No relevant relationships to disclose
Francisco Gabriel Ortega
No relevant relationships to disclose
jose Antonio Lorente
No relevant relationships to disclose
Mayte Delgado
No relevant relationships to disclose
Jose Luis Puche
No relevant relationships to disclose